All News
Duo IL17A,F #SONELOKIMAB
RCT in active #PsA
ACR50 around 46%
Nanobody
to me it looks like #Bimekizumab results
So far low #fungal infections
OP0195
We are over run with + IL17i RCTs in
#psoriatic #arthritis
Impt~market /access/risk/benefit?
#EULAR2024 @eular_org @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Ixokibep a small IL17Ai works in #PsA
16 wks ▶️50% had PASI 100
Fast
40-42% ACR50
Same rate of MDA
Helped enthesitis also
⬆️injection site rx’n
Wow! But where to use vs
2 other IL17Ai and IL17AEi
LB0005
#EULAR24 @eular_org @RheumNow
Janet Pope Janetbirdope ( View Tweet)
The electronic nose, knows?
Exhaled breath volatile organic compounds do surprisingly well in diagnosing RA. Really… takes your breath away
(as seen in @rheuma_doktorin’s highlights)
#EULAR2024 POS0652 @RheumNow https://t.co/OCRHdZZS3Q
David Liew drdavidliew ( View Tweet)
Periodontal disease is a major factor in the development of RA - and that’s the tooth!
in ACPA+ clinically suspect arthralgias,
tooth extraction: adjusted HR 3.10
Population-level dental care?
(as seen in @rheuma_doktorin’s highlights)
#EULAR2024 POS0467 @RheumNow https://t.co/wN8bvBtv40
David Liew drdavidliew ( View Tweet)
The MRI SIJ findings in postpartum patients with buttock/pelvic pain remain stable in a 7 year follow up study. They rarely develop classical MRI features of axial SpA (i.e. erosion, fat > 1 cm in depth, backfill and ankylosis) or are diagnosed as axial SpA within an 8-year… https://t.co/8M0FP65KPS https://t.co/k1ruzjC7Zy
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Long COVID is not equivalent to fibromyalgia - maybe a subgroup but not all of them @rheumnow #EULAR2024 https://t.co/axPrWMsYDb
Links:
Bella Mehta bella_mehta ( View Tweet)
Four phenotypes of chronic back pain suspicious of axial spondyloarthritis (axSpA) in the SPACE cohort. These groups were: They were “axial”, “axSpA with peripheral signs”, “at risk” and “no SpA”. Over a 2 year follow up, Transitions between the four classes over two years were… https://t.co/lF1wtAo46Q https://t.co/BXj1nw0tto
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Planetary health session #EULAR2024
Need to consider these in managing patients.
We in healthcare are contributing to emissions significantly!
@RheumNow https://t.co/Gxyrm5drCE
Links:
Bella Mehta bella_mehta ( View Tweet)
PMR patients get too much steroid.
Data across 27 million people in England, n=39,438 with PMR.
The blue are getting more pred than guidelines.
Like everything in rheum: we need to be giving less pred, not more. Lumping PMR in with GCA won’t help.
#EULAR2024 POS0411 @RheumNow https://t.co/bsi3lrAafm
David Liew drdavidliew ( View Tweet)
#EULAR2024 POS0467 - Periodontal disease related tot he development of #RA
ACPA positive and negative pts.
Tooth extraction in CCP positive pts was associated.
Need tooth history in RA. @RheumNow https://t.co/b9Nb3cd0kd
Links:
Bella Mehta bella_mehta ( View Tweet)
Signing off from #EULAR2024 Vienna 🇦🇹. Well done team on your hard work and comprehensive coverage 👊🏾🙌🏻 @drdavidliew @synovialjoints @AurelieRheumo @bella_mehta @DrMiniDey @Janetbirdope @drpnash @RheumKay @JointMD @andreafava @RheumNow Safe travel 🧳 ✈️🫶🏼 https://t.co/PGtaM02A6j
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Could dogs smell RA? lol...!
Exhaled breath experimental study to diagnose RA?
Volatile organic compounds can detect RA?
#EULAR2024 @RheumNow https://t.co/FiHsZ522In
Links:
Bella Mehta bella_mehta ( View Tweet)
Work ability is impaired in the majority of axSpA patients as measured by the WAI score. 996 patients were included with a mean WAI score of 31.7. Overall, 28%/43% of patients were in poor/moderate work ability, were older, more often obese , had lower education level and… https://t.co/D7oFn31Of5 https://t.co/g79riND9AO
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Deep B cell depletion strategies for Drug resistant RA @RheumNow #EULAR2024
for those which dont want to use CAR-T cells / other options.
Maybe used in other diseases. https://t.co/joRhfWaiDs
Links:
Bella Mehta bella_mehta ( View Tweet)
Is Izokibep the new kid on the block in PsA?
➡️ IL-17A inhibitor
➡️ Complete resolution of enthesitis at 16w
➡️ Overall good safety data
LBA0005 #EULAR2024 @RheumNow https://t.co/8htPOz9YCG
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2024 POS0326 Multicentre cohort in Italy (N=67) showed Benralizumab and Mepolizumab 300mg (EGPA dose) exhibited a significant steroid-sparing effect, with MEPO300 demonstrating superior drug survival. MEPO100 (eosinophilic asthma dose) was numerically inferior @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
EULAR
OP0041 (2024)
COMPARISON OF b/tsDMARDs ABOUT NON-INFLAMMATORY PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS–ANSWER LONGITUDINAL COHORT STUDY. 25% RA have significant non-inflammatory pain https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Links:
Peter Nash drpnash ( View Tweet)
Reassessment of the cut-off values for ASDAS disease activity states in a large, multinational cohort of axSpA patients resulted in cut-offs largely similar to the currently endorsed cut-offs of 1.3, 2.1 and 3.5. Cut-off values between ID and LDA and between LDA and HDA, however,… https://t.co/vECCsmTggW https://t.co/XU7BQBYBdQ
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
EULAR
OP0092 (2024)
INFECTIONS IN PATIENTS WITH RA TREATED WITH JAKi COMPARED TO bDMARDs: AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY) TNF,OMA,JAK 7-10/100 pt.yr no signif diff except for zoster >30,000pts https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Links:
Peter Nash drpnash ( View Tweet)
#EULAR2024 highlight from Prof Pitzalis & team- synovial phosphoproteome analysis in late-stage RA identifies signalling pathways assoc with pathotype & response to RTX & TOC
Study highlights active signalling pathways assoc with pathotype & drug response
OP0218 @RheumNow https://t.co/RZMSgj9T6k
Mrinalini Dey DrMiniDey ( View Tweet)